nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Prednisone—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Glycopyrrolate—Mood swings—Prednisone—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Leflunomide—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Glycopyrrolate—Pruritus—Mometasone—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Glycopyrrolate—Tachycardia—Leflunomide—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Skin disorder—Leflunomide—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Glycopyrrolate—Confusional state—Mycophenolic acid—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Glycopyrrolate—Body temperature increased—Captopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Glycopyrrolate—Abdominal pain—Captopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Glycopyrrolate—Oedema—Mycophenolic acid—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Glycopyrrolate—Dry skin—Prednisone—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Glycopyrrolate—Nausea—Pentoxifylline—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Glycopyrrolate—Infection—Mycophenolic acid—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Glycopyrrolate—Hypotension—Leflunomide—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Glycopyrrolate—Tachycardia—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Glycopyrrolate—Palpitations—Lisinopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Glycopyrrolate—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Glycopyrrolate—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Glycopyrrolate—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Glycopyrrolate—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Glycopyrrolate—Tension—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Insomnia—Leflunomide—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Abdominal distension—Prednisone—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Glycopyrrolate—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Glycopyrrolate—Hypotension—Mycophenolic acid—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Glycopyrrolate—Dyspepsia—Leflunomide—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Glycopyrrolate—Vomiting—Mometasone—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Glycopyrrolate—Dry mouth—Lisinopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Azathioprine—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Glycopyrrolate—Rash—Mometasone—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Glycopyrrolate—Asthenia—Captopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Glycopyrrolate—Dermatitis—Mometasone—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Glycopyrrolate—Confusional state—Lisinopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Headache—Mometasone—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Insomnia—Mycophenolic acid—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Fatigue—Leflunomide—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Glycopyrrolate—Oedema—Lisinopril—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Glycopyrrolate—Pruritus—Captopril—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Glycopyrrolate—Pain—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Glycopyrrolate—Constipation—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Glycopyrrolate—Infection—Lisinopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Glycopyrrolate—Somnolence—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Glycopyrrolate—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Glycopyrrolate—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Glycopyrrolate—Tachycardia—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Glycopyrrolate—Body temperature increased—Azathioprine—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Glycopyrrolate—Abdominal pain—Azathioprine—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Glycopyrrolate—Skin disorder—Lisinopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Glycopyrrolate—Irritability—Methotrexate—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Prednisone—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Leflunomide—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Glycopyrrolate—Fatigue—Mycophenolic acid—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Glycopyrrolate—Mood swings—Methotrexate—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Glycopyrrolate—Nausea—Mometasone—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Glycopyrrolate—Constipation—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Glycopyrrolate—Pain—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Glycopyrrolate—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Glycopyrrolate—Hypotension—Lisinopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Glycopyrrolate—Dizziness—Captopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Glycopyrrolate—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Glycopyrrolate—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Glycopyrrolate—Urticaria—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Glycopyrrolate—Abdominal pain—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Glycopyrrolate—Body temperature increased—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Azathioprine—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Glycopyrrolate—Insomnia—Lisinopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Glycopyrrolate—Vomiting—Captopril—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Glycopyrrolate—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Glycopyrrolate—Rash—Captopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Glycopyrrolate—Dermatitis—Captopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Glycopyrrolate—Somnolence—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Glycopyrrolate—Headache—Captopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Glycopyrrolate—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Glycopyrrolate—Dyspepsia—Lisinopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Glycopyrrolate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Glycopyrrolate—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Glycopyrrolate—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Glycopyrrolate—Infection—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Glycopyrrolate—Fatigue—Lisinopril—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Leflunomide—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Glycopyrrolate—Constipation—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Glycopyrrolate—Pain—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Glycopyrrolate—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Glycopyrrolate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Glycopyrrolate—Nausea—Captopril—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Glycopyrrolate—Asthenia—Leflunomide—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Lisinopril—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Glycopyrrolate—Pruritus—Leflunomide—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Prednisone—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Glycopyrrolate—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Glycopyrrolate—Dysuria—Methotrexate—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Glycopyrrolate—Dizziness—Azathioprine—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Glycopyrrolate—Asthenia—Mycophenolic acid—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Glycopyrrolate—Urticaria—Lisinopril—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Glycopyrrolate—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Glycopyrrolate—Body temperature increased—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Glycopyrrolate—Abdominal pain—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Glycopyrrolate—Pruritus—Mycophenolic acid—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Glycopyrrolate—Vomiting—Azathioprine—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Glycopyrrolate—Pneumonia—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Glycopyrrolate—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Glycopyrrolate—Infestation NOS—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Glycopyrrolate—Infestation—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Glycopyrrolate—Drowsiness—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Glycopyrrolate—Rash—Azathioprine—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Glycopyrrolate—Dermatitis—Azathioprine—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Glycopyrrolate—Flushing—Prednisone—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Glycopyrrolate—Headache—Azathioprine—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Glycopyrrolate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Glycopyrrolate—Dizziness—Leflunomide—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Glycopyrrolate—Constipation—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Glycopyrrolate—Pain—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Glycopyrrolate—Sweating—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Glycopyrrolate—Vomiting—Leflunomide—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Lisinopril—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Glycopyrrolate—Dizziness—Mycophenolic acid—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Epistaxis—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Rash—Leflunomide—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Dermatitis—Leflunomide—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Mental disorder—Prednisone—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Nausea—Azathioprine—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Glycopyrrolate—Headache—Leflunomide—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Glycopyrrolate—Malnutrition—Prednisone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Glycopyrrolate—Erythema—Prednisone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Glycopyrrolate—Asthenia—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Glycopyrrolate—Pruritus—Lisinopril—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Glycopyrrolate—Vomiting—Mycophenolic acid—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Glycopyrrolate—Rash—Mycophenolic acid—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Glycopyrrolate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Glycopyrrolate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Glycopyrrolate—Headache—Mycophenolic acid—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Glycopyrrolate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Glycopyrrolate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Glycopyrrolate—Nausea—Leflunomide—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Glycopyrrolate—Vision blurred—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Glycopyrrolate—Urethral disorder—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Glycopyrrolate—Agitation—Prednisone—systemic scleroderma	0.000985	0.000985	CcSEcCtD
Glycopyrrolate—Dizziness—Lisinopril—systemic scleroderma	0.000974	0.000974	CcSEcCtD
Glycopyrrolate—Nausea—Mycophenolic acid—systemic scleroderma	0.000971	0.000971	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methotrexate—systemic scleroderma	0.000955	0.000955	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000951	0.000951	CcSEcCtD
Glycopyrrolate—Vomiting—Lisinopril—systemic scleroderma	0.000937	0.000937	CcSEcCtD
Glycopyrrolate—Rash—Lisinopril—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Glycopyrrolate—Convulsion—Prednisone—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Glycopyrrolate—Dermatitis—Lisinopril—systemic scleroderma	0.000928	0.000928	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000927	0.000927	CcSEcCtD
Glycopyrrolate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000926	0.000926	CcSEcCtD
Glycopyrrolate—Hypertension—Prednisone—systemic scleroderma	0.000925	0.000925	CcSEcCtD
Glycopyrrolate—Headache—Lisinopril—systemic scleroderma	0.000923	0.000923	CcSEcCtD
Glycopyrrolate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000913	0.000913	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000906	0.000906	CcSEcCtD
Glycopyrrolate—Mental disorder—Methotrexate—systemic scleroderma	0.000902	0.000902	CcSEcCtD
Glycopyrrolate—Malnutrition—Methotrexate—systemic scleroderma	0.000896	0.000896	CcSEcCtD
Glycopyrrolate—Erythema—Methotrexate—systemic scleroderma	0.000896	0.000896	CcSEcCtD
Glycopyrrolate—Dysgeusia—Methotrexate—systemic scleroderma	0.000877	0.000877	CcSEcCtD
Glycopyrrolate—Nausea—Lisinopril—systemic scleroderma	0.000875	0.000875	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Prednisone—systemic scleroderma	0.000875	0.000875	CcSEcCtD
Glycopyrrolate—Oedema—Prednisone—systemic scleroderma	0.000875	0.000875	CcSEcCtD
Glycopyrrolate—Infection—Prednisone—systemic scleroderma	0.000869	0.000869	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Prednisone—systemic scleroderma	0.000858	0.000858	CcSEcCtD
Glycopyrrolate—Tachycardia—Prednisone—systemic scleroderma	0.000854	0.000854	CcSEcCtD
Glycopyrrolate—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000853	0.000853	CcSEcCtD
Glycopyrrolate—Skin disorder—Prednisone—systemic scleroderma	0.00085	0.00085	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Prednisone—systemic scleroderma	0.000846	0.000846	CcSEcCtD
Glycopyrrolate—Vision blurred—Methotrexate—systemic scleroderma	0.000844	0.000844	CcSEcCtD
Glycopyrrolate—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000821	0.000821	CcSEcCtD
Glycopyrrolate—Rash—Mycophenolate mofetil—systemic scleroderma	0.000814	0.000814	CcSEcCtD
Glycopyrrolate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000813	0.000813	CcSEcCtD
Glycopyrrolate—Headache—Mycophenolate mofetil—systemic scleroderma	0.000809	0.000809	CcSEcCtD
Glycopyrrolate—Insomnia—Prednisone—systemic scleroderma	0.000791	0.000791	CcSEcCtD
Glycopyrrolate—Convulsion—Methotrexate—systemic scleroderma	0.000776	0.000776	CcSEcCtD
Glycopyrrolate—Dyspepsia—Prednisone—systemic scleroderma	0.00077	0.00077	CcSEcCtD
Glycopyrrolate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000767	0.000767	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000757	0.000757	CcSEcCtD
Glycopyrrolate—Fatigue—Prednisone—systemic scleroderma	0.000754	0.000754	CcSEcCtD
Glycopyrrolate—Constipation—Prednisone—systemic scleroderma	0.000748	0.000748	CcSEcCtD
Glycopyrrolate—Confusional state—Methotrexate—systemic scleroderma	0.000737	0.000737	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000731	0.000731	CcSEcCtD
Glycopyrrolate—Infection—Methotrexate—systemic scleroderma	0.000726	0.000726	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Prednisone—systemic scleroderma	0.000721	0.000721	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methotrexate—systemic scleroderma	0.000717	0.000717	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000715	0.000715	CcSEcCtD
Glycopyrrolate—Skin disorder—Methotrexate—systemic scleroderma	0.00071	0.00071	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000707	0.000707	CcSEcCtD
Glycopyrrolate—Urticaria—Prednisone—systemic scleroderma	0.000695	0.000695	CcSEcCtD
Glycopyrrolate—Abdominal pain—Prednisone—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Glycopyrrolate—Body temperature increased—Prednisone—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Glycopyrrolate—Hypotension—Methotrexate—systemic scleroderma	0.000683	0.000683	CcSEcCtD
Glycopyrrolate—Insomnia—Methotrexate—systemic scleroderma	0.000661	0.000661	CcSEcCtD
Glycopyrrolate—Somnolence—Methotrexate—systemic scleroderma	0.00065	0.00065	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Prednisone—systemic scleroderma	0.000645	0.000645	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methotrexate—systemic scleroderma	0.000644	0.000644	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000631	0.000631	CcSEcCtD
Glycopyrrolate—Fatigue—Methotrexate—systemic scleroderma	0.00063	0.00063	CcSEcCtD
Glycopyrrolate—Asthenia—Prednisone—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Glycopyrrolate—Pain—Methotrexate—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Glycopyrrolate—Pruritus—Prednisone—systemic scleroderma	0.000619	0.000619	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methotrexate—systemic scleroderma	0.000603	0.000603	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000598	0.000598	CcSEcCtD
Glycopyrrolate—Urticaria—Methotrexate—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Glycopyrrolate—Dizziness—Prednisone—systemic scleroderma	0.000579	0.000579	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methotrexate—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Glycopyrrolate—Body temperature increased—Methotrexate—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Glycopyrrolate—Vomiting—Prednisone—systemic scleroderma	0.000556	0.000556	CcSEcCtD
Glycopyrrolate—Rash—Prednisone—systemic scleroderma	0.000552	0.000552	CcSEcCtD
Glycopyrrolate—Dermatitis—Prednisone—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Glycopyrrolate—Headache—Prednisone—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methotrexate—systemic scleroderma	0.000539	0.000539	CcSEcCtD
Glycopyrrolate—Asthenia—Methotrexate—systemic scleroderma	0.000525	0.000525	CcSEcCtD
Glycopyrrolate—Nausea—Prednisone—systemic scleroderma	0.00052	0.00052	CcSEcCtD
Glycopyrrolate—Pruritus—Methotrexate—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Glycopyrrolate—Dizziness—Methotrexate—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Glycopyrrolate—Vomiting—Methotrexate—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Glycopyrrolate—Rash—Methotrexate—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Glycopyrrolate—Dermatitis—Methotrexate—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Glycopyrrolate—Headache—Methotrexate—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Glycopyrrolate—Nausea—Methotrexate—systemic scleroderma	0.000434	0.000434	CcSEcCtD
